Skip to content
TrustList
AmorChem logo
Investor

AmorChem

Canadian early-stage venture fund creating biotech companies from academic research

AmorChem cover

About AmorChem

Early stage venture funding for research in Canadian universities is the business of AmorChem. The firm says it has been active since 2011 and has financed more than thirty research programs in academia. It describes its work as a close look at the science behind each project, with its investments focused on translational research, the step that moves a discovery towards a viable business.

A model built on the science

AmorChem argues that early investors need to understand the work they fund, so its team takes a deep dive into the science before committing money. It presents this as a venture model suited to research that has not yet been turned into a business, and it describes the moment of early funding as the first spark that a new company needs.

Companies created from academic work

According to the company, it has helped establish several biotech companies, each built around its own therapeutic approach. One example is a delivery technology that was built on RNA and then exited when the business was sold to a company based in New York. The firm also says it has helped found a Canadian company from academic work, and that it works with scientist entrepreneurs who want to commercialise their results.

Ambition for the Canadian ecosystem

The firm says its aim is to lead early-stage funding for biotech in Canada, building a collaborative community of start-ups that come out of academic research. The firm sees that community as a way of fostering a new generation of science entrepreneurs.

TrustList summary

AmorChem is an early-stage venture fund that turns academic research into new biotech companies. It has been active since 2011 and aims to become the main early-stage fund of its kind in Canada. The firm looks closely at the science behind each project rather than only the business plan.

Services

  • Research funding: has financed over 30 academic research programmes.
  • Company creation: helps establish biotech businesses around promising therapeutic ideas.
  • Translational focus: invests in the research needed to bridge the gap between discovery and a viable company.
  • Community building: aims to grow a collaborative group of biotech start-ups and science entrepreneurs.

Who it works with

The fund works with university researchers and scientist-entrepreneurs in Canada. Its social posts mention NuChem, a company it helped create, and Find Therapeutics.

Key facts

  • Region: Canada
  • Active since: 2011
  • Programmes financed: more than 30

Summary written by TrustList from the business's own published information, Nov 2026.

Categories & features

  • It
  • Science
  • De
  • Quebec
  • Early Stage
  • Series

What the business tells TrustList

Founded
2011 (15 years) evidence sent

Ask TrustList to introduce you to AmorChem

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA - Google Privacy Policy and Terms apply.

Reviews

Write the first review of AmorChem

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about AmorChem.

AmorChem alternatives

Similar listings buyers compare against this one.

Midwest venture capital firm investing in early-stage healthcare companies, from diagnostics to life science tools

A Toronto venture firm investing in early-stage Canadian B2B technology companies

Colorado seed-stage venture firm that backs founders across the United States

Vienna-based venture capital firm investing in early-stage digital health and wellbeing start-ups across Europe and the US

Venture investor supporting founders building deep technology companies with capital and experience

Canadian life sciences company builder providing seed capital, lab facilities and talent programmes

Healthcare venture capital firm investing in therapeutics and discovery platforms for unmet medical needs